OTCPK:LXGT.F

Stock Analysis Report

Executive Summary

Lexington Biosciences, Inc. develops and commercializes non-invasive diagnostic products for cardiovascular health for home and clinical use.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Lexington Biosciences has significant price volatility in the past 3 months.
  • Lexington Biosciences is not covered by any analysts.

Share Price & News

How has Lexington Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-11.5%

OTCPK:LXGT.F

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

-97.1%

OTCPK:LXGT.F

9.9%

US Medical Equipment

1.6%

US Market

LXGT.F underperformed the Medical Equipment industry which returned 9.1% over the past year.

LXGT.F underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

LXGT.FIndustryMarket
7 Day-11.5%0.5%-0.02%
30 Day-52.2%0.09%2.7%
90 Day-74.3%2.0%1.4%
1 Year-97.1%-97.1%10.8%9.9%3.8%1.6%
3 Yearn/a69.0%63.9%45.2%35.8%
5 Yearn/a136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Lexington Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Lexington Biosciences undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Lexington Biosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lexington Biosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of LXGT.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Lexington Biosciences regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Lexington Biosciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lexington Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of LXGT.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Lexington Biosciences's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Lexington Biosciences performed over the past 5 years?

58.9%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Lexington Biosciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Lexington Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Lexington Biosciences's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Lexington Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Lexington Biosciences has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Lexington Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Lexington Biosciences's financial position?


Financial Position Analysis

Lexington Biosciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Lexington Biosciences has no long term commitments.


Debt to Equity History and Analysis

Lexington Biosciences has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Lexington Biosciences's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Lexington Biosciences has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Lexington Biosciences has less than a year of cash runway based on current free cash flow.

Lexington Biosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 19.6% each year.


Next Steps

Dividend

What is Lexington Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Lexington Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Lexington Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Lexington Biosciences has not reported any payouts.

Unable to verify if Lexington Biosciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Lexington Biosciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Lexington Biosciences's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average board tenure


CEO

Eric Willis (47yo)

2.8yrs

Tenure

CA$263,594

Compensation

Mr. Eric Willis had been the President of Lexington Biosciences, Inc. since May 2017 and serves as its Chief Executive Officer and Secretary since December 21, 2016. Mr. Willis served as the Chief Executiv ...


CEO Compensation Analysis

Eric's remuneration is lower than average for companies of similar size in United States of America.

Eric's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

2.2yrs

Average Tenure

50yo

Average Age

The average tenure for the Lexington Biosciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Nick Furber (45yo)

    Chief Financial Officer

    • Tenure: 2.8yrs
    • Compensation: CA$40.66k
  • Eric Willis (47yo)

    CEO, Secretary & Director

    • Tenure: 2.8yrs
    • Compensation: CA$263.59k
  • Donald McInnes

    • Tenure: 0yrs
  • Jonathan Maltz

    Chief Scientific Advisor

    • Tenure: 2.2yrs

Board Members

  • Doug Janzen (50yo)

    Board Chairman

    • Tenure: 0yrs
  • Eric Willis (47yo)

    CEO, Secretary & Director

    • Tenure: 2.8yrs
    • Compensation: CA$263.59k
  • Greg Robertson

    Member of Medical Advisory Board

    • Tenure: 2.2yrs
  • John Disher (61yo)

    Independent Director

    • Tenure: 2.8yrs
  • Jonathan Maltz

    Chief Scientific Advisor

    • Tenure: 2.2yrs
  • James Wall

    Member of Medical Advisory Board

    • Tenure: 2.2yrs
  • Jeffrey Olgin

    Member of Medical Advisory Board

    • Tenure: 2.2yrs

Company Information

Lexington Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lexington Biosciences, Inc.
  • Ticker: LXGT.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$170.407k
  • Listing Market Cap: CA$128.609k
  • Shares outstanding: 3.79m
  • Website: https://www.lexingtonbiosciences.com

Location

  • Lexington Biosciences, Inc.
  • 1055 West Hastings Street
  • Suite 1900
  • Vancouver
  • British Columbia
  • V6E 2E9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1ZC1DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2017
LNBCNSX (Canadian National Stock Exchange)YesCommon SharesCACADMay 2017
LXGT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMay 2017

Biography

Lexington Biosciences, Inc. develops and commercializes non-invasive diagnostic products for cardiovascular health for home and clinical use. It develops HeartSentry, a device for the personalized measurem ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 00:42
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.